Skip to main content
SpringerLink
Log in

Nachsorge beim Hodentumor lohnt sich

Rezidive sind heilbar

Follow-up of testicular cancer is worthwhile

Recurrences are curable

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Patienten mit Keimzelltumoren des Hodens haben heute — im Vergleich zu anderen Tumorerkrankungen — eine außerordentlich große Chance auf dauerhafte Heilung. Problematische Situationen entstehen bei Rezidiven. Je später sie entdeckt werden, je voluminöser sie sind, desto intensiver entwickelt sich die Therapie und um so schlechter wird die Prognose. Neben der rechtzeitigen Erkennung von Rezidiven ist es auch Aufgabe der Nachsorge, die therapieassoziierten Morbiditäten zu kontrollieren. Die Nachsorge muss daher in erfahrener Hand histologie-, stadien- und therapiebezogen durchgeführt werden.

Abstract

Patients with germ cell tumours of the testis can have an extremely favourable chance of cure when compared to other malignancies. Therapeutic problems may arise with recurrent disease. High tumour burden can result when relapses are diagnosed too late and the prognosis will deteriorate, consecutively, even in spite of intensified therapeutic endeavours. Apart from early detection of recurrent disease, the follow-up schedule of germ cell cancer aims to identify and manage treatment-related morbidities, e.g. vascular problems and second neoplasms, respectively. Follow-up examinations should be tailored to the individual situation taking into account the particular risk of relapse based on histology, stage and treatment previously applied. In light of the rarity of the disease and according to the complexity of managing this malignancy, follow-up should be conducted by particularly experienced institutions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Beyer J, Bokemeyer C (2004) Chemotherapie von Keimzelltumoren. Urologe A 43: 1507–1513

    Article  PubMed  Google Scholar 

  2. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L (1998) Analysis of risk factores for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77: 1355–1362

    PubMed  Google Scholar 

  3. Chaudhary UB, Haldas JR (2003) Long-term complications of chemotherapy for germ cell tumors, Drugs 63:1565–1577

    Google Scholar 

  4. Dearnaley DP, Huddart RA, Horwich A (2001) Managing testicular cancer. Br Med J 322: 1583–1588

    Google Scholar 

  5. Dieckmann KP, Albers P, Classen J et al. (2005). Late relapse of testicular germ cell neoplasms: A descriptive analysis of 122 cases. J Urol 173: 824–829

    Article  PubMed  Google Scholar 

  6. Dieckmann KP, Loy V (2003) False-negative biopsies for the diagnosis of testicular intraepithelial neoplasia (TIN) — an update. Eur Urol 43: 516–521

    Article  PubMed  Google Scholar 

  7. Dieckmann KP, Boeckmann W, Brosig W, Jonas D, Bauer HW (1986) Bilateral testicular germ cell tumors. Report of nine cases and review of the literature. Cancer 57: 1254–1258

    PubMed  Google Scholar 

  8. Fossa SD (2004) Long-term sequelae after cancer therapy — survivorship after treatment for testicular cancer. Acta Oncol 43: 134–141

    Article  PubMed  Google Scholar 

  9. Heidenreich A, Weissbach L, Höltl W, Albers P, Kliesch S, Köhrmann KU, Dieckmann KP (2001) Organ sparing surgery for malignant germ cell tumors of the testis. J Urol 166: 2161–2165

    Article  PubMed  Google Scholar 

  10. Husband J (1996) Advances in tumor imaging. In Horwich A (ed) Testicular cancer. Investigation and management, 2nd edn. Chapman & Hall, London, pp 19–34

  11. International Germ Cell Cancer Collaborative Group (IGCCCG) (1997) The International Germ Cell Consensus Classification: a prognostic factor based staging system for metastatic germ cell cancer. J Clin Oncol 15: 594–603

    PubMed  Google Scholar 

  12. Jakob A, Kollmannsberger C, Kanz L, Bokemeyer C (1998) Spättoxizität nach Chemotherapie maligner Hodentumoren. Urologe A 37: 635–647

    Article  PubMed  Google Scholar 

  13. Jewett MAS, Grabowski A, McKiernan J (2003) Management of recurrence and follow-up strategies for patients with nonseminoma testis cancer. Urol Clin North Am 30: 819–830

    Article  PubMed  Google Scholar 

  14. Jones RH, Vasey PA (2003) Part II: testicular cancer — management of advanced disease. Lancet Oncol 4: 738–747

    Article  PubMed  Google Scholar 

  15. Kollmannsberger C, Bokemeyer C (2003) Therapie von metastasierten Keimzelltumoren bei Patienten mit „Good prognosis“ Kriterien. Onkologe 9: 980–984

    Article  Google Scholar 

  16. Kranz A, Lampante L, Sparwasser H (1988) Sonographie des Abdomens. Beitr Onkol 28: 110–122

    Google Scholar 

  17. Krege S, Schmoll HJ, Souchon R (2001) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren. Ergebnisse einer Update-Konferenz auf Grundlage evidenzbasierter Medizin (EBM). Urologe A 40: 137–147

    Article  PubMed  Google Scholar 

  18. Leitlinien zur Diagnostik und Therapie von Hodentumoren auf der Grundlage evidenzbasierter Medizin, 1. Aufl. (2002) Souchon R, Schmoll HJ, Krege S, German Testicular Cancer Study Group im Auftrag der Deutschen Krebsgesellschaft (Hrsg) Zuckschwerdt, München Bern

  19. Oosterhof GO, Verlind J (2004) Testicular tumours (nonseminomatous). BJU Int 94: 1196–1201

    Article  PubMed  Google Scholar 

  20. Patel MI, Motzer RJ, Sheinfeld J (2003) Management of recurrence and follow-up strategies for patients with seminoma and selected high-risk groups. Urol Clin North Am 30: 803–817

    Article  PubMed  Google Scholar 

  21. Pottek T (2004) Retroperitoneale Lymphadenektomie beim Hodentumor. Urologe A 43: 1514–1520

    Article  PubMed  Google Scholar 

  22. Schmoll HJ, Souchon R, Krege S et al. (2004) European Consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCG). Ann Oncol 15: 1377–1399

    Article  PubMed  Google Scholar 

  23. Schölermann KH, Dettmann R, Hartmann M (1996) Die risikogesteuerte Hodentumornachsorge. Urologe A 35: 326–330

    PubMed  Google Scholar 

  24. Schrader M, Weissbach L, Miller K (2004) Therapie von Hodentumoren. Illusion oder Realität — ändern Leitlinien die Versorgungsergebnisse? Dtsch Ärztebl A 101: 2612–2618

    Google Scholar 

  25. Shelley MD, Burgon K, Mason MD (2002) Treatment of testicular germ-cell cancer: a Cochrane evidence-based systematic review. Cancer Treat Rev 28: 237–253

    Article  PubMed  Google Scholar 

  26. Sobin LH, Wittekind C (eds) (2002) UICC: TNM classification of malignant tumours, 6th edn. Wiley-Liss, New York

  27. Travis LB, Curtis RE, Storm H et al. (1997) Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89: 1429–1439

    Article  PubMed  Google Scholar 

  28. van Dijk Mv, Steyerberg EW, Stenning SP, Dusseldorp E, Habbema JDF (2004) Survival of patients with nonseminomatous germ cell cancer: a review of the IGCC classification by Cox regression and recursive partitioning. Br J Cancer 90: 1176–1183

    Article  PubMed  Google Scholar 

  29. Vaughn DJ, Gignar GA, Meadows AT (2002) Long-term medical care of testicular cancer survivors. Ann Intern Med 136: 463–470

    PubMed  Google Scholar 

Download references

Interessenkonflikt:

Die Autoren erklären, dass kein Interessenkonflikt im Sinne der Richtlinien des „International Committee of Medical Journal Editors“ besteht.

Author information

Authors and Affiliations

  1. Abteilung Urologie, Bundeswehrkrankenhaus, Hamburg

    T. S. Pottek

  2. Albertinen-Krankenhaus, Hamburg

    K.-P. Dieckmann

  3. Abteilung Urologie, Bundeswehrkrankenhaus, Lesserstraße 180, 22049, Hamburg

    T. S. Pottek

Authors
  1. T. S. Pottek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K.-P. Dieckmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. S. Pottek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pottek, T.S., Dieckmann, KP. Nachsorge beim Hodentumor lohnt sich. Urologe 44, 1024–1030 (2005). https://doi.org/10.1007/s00120-005-0881-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-005-0881-x

Schlüsselwörter

Keywords

Search

Navigation